837423-56-0Relevant academic research and scientific papers
USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS
-
Paragraph 00407-00408, (2016/04/20)
The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inh
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: Synthesis, SAR, and in vivo antiinflammatory activity
Martin, Matthew W.,Newcomb, John,Nunes, Joseph J.,McGowan, David C.,Armistead, David M.,Boucher, Christina,Buchanan, John L.,Buckner, William,Chai, Lilly,Elbaum, Daniel,Epstein, Linda F.,Faust, Theodore,Flynn, Shaun,Gallant, Paul,Gore, Anu,Gu, Yan,Hsieh, Faye,Huang, Xin,Lee, Josie H.,Metz, Daniela,Middleton, Scot,Mohn, Deanna,Morgenstern, Kurt,Morrison, Michael J.,Novak, Perry M.,Oliveira-Dos-Santos, Antonio,Powers, David,Rose, Paul,Schneider, Stephen,Sell, Stephanie,Tudor, Yanyan,Turci, Susan M.,Welcher, Andrew A.,White, Ryan D.,Zack, Debra,Zhao, Huilin,Zhu, Li,Zhu, Xiaotian,Ghiron, Chiara,Amouzegh, Patricia,Ermann, Monika,Jenkins, James,Johnston, David,Napier, Spencer,Power, Eoin
, p. 4981 - 4991 (2007/10/03)
The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and NK cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the synthesis, structure-activity relationships, and pharmacological characterization of 2-aminopyrimidine carbamates, a new class of compounds with potent and selective inhibition of Lck. The most promising compound of this series, 2,6-dimethylphenyl 2-((3,5-bis(methyloxy)-4-((3-(4-methyl-1-piperazinyl)propyl)- oxy)phenyl)amino)-4-pyrimidinyl(2,4-bis(methyloxy)phenyl)carbamate (43) exhibits good activity when evaluated in in vitro assays and in an in vivo model of T cell activation.
